Notch Signaling in Prevention And Therapy: Fighting Cancer with a Two-Sided Sword

Reichrath, Jörg; Reichrath, Sandra

doi:10.1007/978-3-030-55031-8_1

Cited by 5 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous study has indicated that Notch signaling is critical to cancer cell proliferation, apoptosis escaping, angiogenesis, EMT cascade, and stemness maintaining [ 32 ]. Because of Notch pathway is upregulated in HCC patients, the targeted treatment for anti-Notch pathway in HCC patients will need considerable on the upstream of Notch pathway, which are important to reduce the major side effects [ 33 ]. Our study indicated that MCM6 could activate the Notch pathway.…”

Section: Discussionmentioning

confidence: 99%

MCM6 Promotes Hepatocellular Carcinoma Progression via the Notch Pathway: Clinical, Functional, and Genomic Insights

Hou

Zeng

Li³

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. To evaluate the expression profile of MCM6 in HCC and the relationship between MCM6 level and clinicopathological parameters through bioinformatics analysis of several databases. Methods. MCM expression level, clinical parameters, survival data, and gene set enrichment analysis were analyzed by bioinformatics database, including Oncomine™, UALCAN, HCCDB, TCGA, cBioPortal, and LinkedOmics. Real-time PCR, western blotting, and IHC staining were conducted to identify the expression of MCM6 in HCC compared to normal liver tissues. Results. Bioinformatics analysis indicated that the mRNA of MCM6 was obviously increased in multiple cancer types, especially in HCC. MCM6 level was positively associated with multiple clinical parameters (stage 3 and grades 3 and 4) and negatively associated with patient outcomes (overall survival). Moreover, enrichment of functions and signaling pathways analysis of MCM6 suggested that MCM6 might mediate DNA replication and cellular metabolism to promote the development and progression of HCC. Furthermore, IHC staining and western blotting indicated that the MCM6 was enhanced in HCC tissue, and MCM6 could promote HCC proliferation in activating Notch pathway via WB and bioinformatic analysis. Conclusion. This study actually revealed the expression and related functions of MCM6 in HCC. Furthermore, MCM6 is a carcinogenic role in activating Notch pathway to promote HCC cell proliferation, which may be a new prognostic biomarker and therapeutic target for HCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

MCM6 Promotes Hepatocellular Carcinoma Progression via the Notch Pathway: Clinical, Functional, and Genomic Insights

Hou

Zeng

Li³

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

Section: Treatment and Drug Resistance Of Crc Associated With Emtmentioning

confidence: 99%

“…56 Non-selective GSIs are often referred to as Notch inhibitors because they can inhibit tumor metastasis and EMT development by the suppressing the Notch pathway. 57 Currently, GIS has demonstrated antitumor effects in a number of preclinical models. 58 Cetuximab (Erbitux, C225) is a closed monoclonal antibody for the epidermal growth factor receptor (EGFR) 59 that competitively blocks the EGFR signaling pathway and inhibits the proliferation of tumor cells; therefore, it is an effective targeted therapeutic agent for the treatment of CRC.…”

Section: Targeted Therapy For Treatment and Drug Resistance In Emt-as...mentioning

confidence: 99%

Research Progress of Epithelial-mesenchymal Transition Treatment and Drug Resistance in Colorectal Cancer

2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common malignancies in the world that seriously affects human health. Activation of epithelial-mesenchymal transition (EMT) is a physiological phenomenon during embryonic development that is essential for cell metastasis. EMT participates in various biological processes associated with trauma repair, organ fibrosis, migration, metastasis, and infiltration of tumor cells. EMT is a new therapeutic target for CRC; however, some patients with CRC develop resistance to some drugs due to EMT. This review focuses specifically on the status of treatments that target the EMT process and its role in the therapeutic resistance observed in patients with CRC.

show abstract

“…In malignancies, the Notch signaling pathway is activated. Direct cell‐to‐cell interface is facilitated by its abnormal activation, which also performs a remarkable function in tumor onset, progression survival, proliferation, invasion, and metastasis 170 …”

Section: Signaling Pathways In Osmentioning

confidence: 99%

Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies

Shen

Lan

et al. 2023

MedComm

View full text Add to dashboard Cite

Osteosarcoma (OS) is a highly prevalent bone malignancy among adolescents, accounting for 40% of all primary malignant bone tumors. Neoadjuvant chemotherapy combined with limb‐preserving surgery has effectively reduced patient disability and mortality, but pulmonary metastases and OS cells' resistance to chemotherapeutic agents are pressing challenges in the clinical management of OS. There has been an urgent need to identify new biomarkers for OS to develop specific targeted therapies. Recently, the continued advancements in genomic analysis have contributed to the identification of clinically significant molecular biomarkers for diagnosing OS, acting as therapeutic targets, and predicting prognosis. Additionally, the contemporary molecular classifications have revealed that the signaling pathways, including Wnt/β‐catenin, PI3K/AKT/mTOR, JAK/STAT3, Hippo, Notch, PD‐1/PD‐L1, MAPK, and NF‐κB, have an integral role in OS onset, progression, metastasis, and treatment response. These molecular classifications and biological markers have created new avenues for more accurate OS diagnosis and relevant treatment. We herein present a review of the recent findings for the modulatory role of signaling pathways as possible biological markers and treatment targets for OS. This review also discusses current OS therapeutic approaches, including signaling pathway‐based therapies developed over the past decade. Additionally, the review covers the signaling targets involved in the curative effects of traditional Chinese medicines in the context of expression regulation of relevant genes and proteins through the signaling pathways to inhibit OS cell growth. These findings are expected to provide directions for integrating genomic, molecular, and clinical profiles to enhance OS diagnosis and treatment.

show abstract

Notch Signaling in Prevention And Therapy: Fighting Cancer with a Two-Sided Sword

Cited by 5 publications

References 22 publications

MCM6 Promotes Hepatocellular Carcinoma Progression via the Notch Pathway: Clinical, Functional, and Genomic Insights

MCM6 Promotes Hepatocellular Carcinoma Progression via the Notch Pathway: Clinical, Functional, and Genomic Insights

Research Progress of Epithelial-mesenchymal Transition Treatment and Drug Resistance in Colorectal Cancer

Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies

Contact Info

Product

Resources

About